Greenwood Capital Associates LLC Makes New Investment in Pfizer Inc. (NYSE:PFE)

Greenwood Capital Associates LLC purchased a new stake in Pfizer Inc. (NYSE:PFE) during the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 50,899 shares of the biopharmaceutical company’s stock, valued at approximately $1,473,000.

Several other institutional investors also recently made changes to their positions in the stock. Olistico Wealth LLC acquired a new position in shares of Pfizer in the 2nd quarter valued at about $25,000. MFA Wealth Advisors LLC purchased a new position in Pfizer in the second quarter valued at approximately $29,000. Quarry LP purchased a new position in Pfizer in the second quarter valued at approximately $31,000. Financial Connections Group Inc. acquired a new position in Pfizer during the second quarter valued at approximately $34,000. Finally, ESL Trust Services LLC acquired a new stake in shares of Pfizer in the first quarter worth $37,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.06% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Barclays boosted their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. Finally, UBS Group upped their target price on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and an average target price of $33.58.

Pfizer Stock Down 1.2 %

PFE stock opened at $27.76 on Tuesday. The firm has a fifty day moving average price of $29.01 and a two-hundred day moving average price of $28.63. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54. The firm has a market cap of $157.31 billion, a price-to-earnings ratio of 37.51, a PEG ratio of 0.89 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.40%. Pfizer’s revenue was up 31.2% on a year-over-year basis. During the same quarter last year, the company posted ($0.17) earnings per share. Research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 6.05%. Pfizer’s payout ratio is currently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.